Abstract

The emergence of new antiviral agents in the wake of the recent pandemic has underscored the critical importance of pharmacokinetic profiling in drug development. This review highlights the pharmacokinetic characteristics of novel antiviral compounds, focusing on absorption, distribution, metabolism, and excretion (ADME) parameters. By analyzing data from recent clinical trials and studies, we explore how these profiles impact therapeutic efficacy, safety, and patient adherence. Key lessons learned during the pandemic emphasize the need for rapid assessment methods and adaptive trial designs to evaluate antiviral drugs effectively. Additionally, the review discusses the implications of pharmacokinetic variability among diverse patient populations and the importance of precision medicine in optimizing treatment outcomes. As we move forward, the insights gained from pharmacokinetic profiling will be instrumental in guiding the development of effective antiviral therapies and improving public health responses to future viral threats